Discover Advancements in the Treatment of Myelosuppression

Join Dr. Edward Kim, Dr. Mohamed Mohamed, and Dana Herndon, RN, in a live broadcast to learn more about the current treatment landscape of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC).

Lung cancer is the leading cause of cancer-related death in the United States.1 About 13% of all lung cancer cases in the United States are small cell lung cancer (SCLC), and most patients are diagnosed with extensive-stage (ES)-SCLC.2,3 The prognosis for patients with SCLC is poor, with an overall 5-year survival rate of 6% and just 3% among those with distant metastasis.2

Systemic chemotherapy in combination with immune checkpoint inhibitors is the standard of care for patients with ES-SCLC.4 However, these regimens present a treatment challenge due to multilineage myelosuppression. Myelosuppression increases a patient’s risk for bleeding complications, infections, and secondary malignancies,5 and is the most common reason for dose reductions, delays, and discontinuation of chemotherapy.

Join Dr. Kim, Dr. Mohamed, and Dana Herndon, RN, in a live broadcast to learn more about the current treatment landscape of chemotherapy-induced myelosuppression in patients with ES-SCLC. These leading experts will discuss the clinical data, safety, and considerations of a therapeutic option for chemotherapy-induced myelosuppression.

Program Objectives

  • Review the burden and current treatment landscape of chemotherapy-induced myelosuppression
  • Introduce the mechanism of action and safety and efficacy data
  • Explore adverse reactions, dosing and administration, and the patient support program

The broadcast will be offered at the following times:

Thursday, 3/25 at 6:00 PM ET
Thursday, 3/25 at 8:00 PM ET
Friday, 3/26 at 12:00 PM ET

References:

  1. American Cancer Society. Key statistics for lung cancer. Accessed January 11, 2021. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
  2. American Society of Clinical Oncology. Lung cancer - small cell: statistics. Accessed January 11, 2021. https://www.cancer.net/cancer-types/lung-cancer-small-cell/statistics
  3. American Society of Clinical Oncology. Lung cancer - small cell: stages. Accessed January 11, 2021. https://www.cancer.net/cancer-types/lung-cancer-small-cell/stages
  4. National Comprehensive Cancer Network. Small Cell Lung Cancer (Version 1.2021). Accessed August 11, 2020. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf.
  5. Kurtin S. Myeloid toxicity of cancer treatment. J Adv Pract Oncol. 2012;3(4):209-224.

US-2000120 3/2021